Navigation Links
Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
Date:9/3/2013

KANSAS CITY, Kan., Sept. 3, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), participated in several business development and leadership events during "CVC Week" in Kansas City.   The Conference for Veterinary Care (CVC) and adjunctive events, including the 2013 Animal Health Research Symposium and the Animal Health Early+Mid-Stage Investment Forum, were organized from August 23-27, 2013 to advance the growth and science of veterinary and animal care.

Showcasing its leadership position in the development and commercialization of innovative medications for pets, Aratana's Head of Drug Evaluation and Development, Ernst Heinen, DVM, Ph.D., delivered a presentation during the 2013 Animal Health Research Symposium entitled, "From Human Research To Pet Therapeutics."  Dr. Heinen's presentation highlighted the need for improved medications for dogs and cats, and the greenfield opportunity to develop drugs presently for human applications into therapeutics specifically for use in pets.

Separately, Aratana's Chief Scientific Officer, Linda Rhodes, VMD, Ph.D., a pioneer in the veterinary and animal health industry, presented the "2013 Innovation Award" at the Animal Health Early+Mid-Stage Investment Forum.   Sponsored by Aratana, the Innovation Award recognizes a single company that combines the most promising scientific and business opportunity. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "CVC Week is one of the significant annual events in animal health and veterinary care, and since we are a Kansas City-headquartered company, we are particularly pleased to play a leadership role in the emerging pet therapeutics space."

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.


Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana to Participate in Leerink Swanns November Management Access Days
2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
Breaking Medicine News(10 mins):